338 results on '"Bodini, G."'
Search Results
2. Efficient laser-driven proton acceleration from a petawatt contrast-enhanced second harmonic mixed-glass laser system.
3. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY
4. T.01.5: AUTOIMMUNE CHRONIC ATROPHIC GASTRITIS: IMPROPER USE OF PPI IS ASSOCIATED WITH INCREASED ATROPHIA AND GASTRIC INTESTINAL METAPLASIA
5. P965 Ulcerative proctitis treated with biologics: is it too hard to treat?
6. P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy
7. P603 Comparison of the safety and efficacy of ustekinumab and vedolizumab in patients with Crohn’s disease. - A systematic review and meta-analysis of propensity score matched cohort studies
8. P1066 The real-life use of the Crohn's disease exclusion diet (CDED) in adults with mild-to-moderate Crohn's disease activity: an interim analysis of an open-label randomized controlled trial
9. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study
10. P1127 Diagnostic delay and economic burden in IBD: a multicenter italian experience in patients treated with biologics
11. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
12. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: Data of a national study (ESCAPE-IBD)
13. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
14. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
15. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY
16. OC.16.1 EFFECT OF HIATAL HERNIA AND ESOPHAGOGASTRIC JUNCTION MORPHOLOGY ON OESOPHAGEAL MOTILITY: NEW EVIDENCES FROM HIGH RESOLUTION MANOMETRY
17. N25 Diagnostic delay and economic burden in ibd: a multicenter italian experience in patients treated with biologics
18. Optimal management of constipation associated with irritable bowel syndrome
19. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study
20. PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY
21. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS
22. OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
23. OC.08.3 IMPACT OF ENVIRONMENTAL CHANGES FORCED BY PANDEMIC RESTRICTIVE MEASURES ON THE DEVELOPMENT AND COURSE OF IRRITABLE BOWEL SYNDROME
24. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
25. IBD and Covid-19 in Italy: comparisons between first and second pandemic wave
26. P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave
27. P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors
28. Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohnʼs disease
29. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease
30. Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?
31. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study
32. Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study
33. Letter: biological therapies are effective for prevention of post-operative Crohnʼs disease recurrence
34. OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
35. T04.01.9 IMPACT OF ULCERATIVE COLITIS AND ITS ASSOCIATED DISEASE BURDEN ON ITALIAN PATIENTS: THE FIRST-YEAR ANALYSIS OF THE ICONIC STUDY
36. P465 Therapeutic drug monitoring in Crohn’s disease patients, a comparison between homogeneous mobility shift assay and point of care method
37. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma
38. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis
39. Mediterranean diet and NAFLD: What we know and questions that still need to be answered
40. OC.03.7: COMPARISON OF THE SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH CROHN'S DISEASE - A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROPENSITY SCORE MATCHED COHORT STUDIES.
41. Prevalence of anaemia in Italian patients with inflammatory bowel disease: Preliminary results of the observational multi-centre IG-IBD study RIDART 1
42. PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
43. P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION
44. OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY
45. PC.01.4 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
46. OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY
47. P.07.4 HIGH ANTI-TNF ALFA DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
48. P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study
49. P783 Long-term colectomy rate in acute severe ulcerative colitis. An observational multi-centre study on behalf of IG-IBD (Italian group for the study of inflammatory bowel disease)
50. P576 Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.